Background and Purpose-The aim of the study was to investigate the utility of iodine contrast agent leakage (the iodine sign) analyzed by Gemstone spectral imaging in early hematoma formation compared with that of the spot sign for predicting early hematoma expansion (HE) and poor functional outcomes. Methods-From 2014 to 2017, 91 patients with spontaneous intracerebral hemorrhage who underwent spectral computed tomography angiography within 6 hours of spontaneous intracerebral hemorrhage onset were prospectively included in our study. We defined a positive iodine sign as tiny enhancing foci within the hematoma on Gemstone spectral imaging and an iodine concentration inside the foci of >7.82 (100 µg/mL). Univariate and multivariate logistical regression analyses were performed to assess risk factors for HE, and the predictive value of HE was analyzed. 
S
pontaneous intracerebral hemorrhage (SICH), one of the most devastating diseases, accounts for 10% to 30% of all strokes worldwide. 1, 2 The poor outcomes of SICH, which has a 1-month mortality rate ranging from 30% to 50%, remain a major concern. 3 Early hematoma expansion (HE), which occurs in approximately one-third of SICH patients, has been identified as a highly predictive factor of early neurological deterioration and poor functional outcomes. 4 The initial hematoma volume, Glasgow coma scale score, age, and intraventricular hemorrhage are all independent predictors of poor outcomes, [5] [6] [7] but a reliable method to identify the risk factors of poor outcomes is still lacking. Most previous studies have suggested that tiny enhancing foci within the hematoma on computed tomography angiography (CTA), called the spot sign, are a surrogate predictor for HE and poor outcomes. [8] [9] [10] The early identification of patients at increased risks for hematoma growth is important for targeted hemostatic therapy. However, a recent study evaluating the accuracy of using the spot sign for predicting HE reported its sensitivity, specificity, positive predictive value, and negative predictive value to be 34.6%, 96.2%, 92.3%, and 52.4%, respectively. 11 Because of its low sensitivity, a more sensitive method to predict early HE is urgently needed.
As a promising scanning mode, Gemstone spectral imaging (GSI) can directly separate iodine from the blood and reflect the iodine concentration (IC) by monochromatic imaging. [12] [13] [14] Therefore, a new method, called the iodine sign, which directly reflects leaking iodinated contrast, was created to predict HE. After performing single-phase spectral CTA, we analyzed the 2 images (CTA arterial image and spectral image) to investigate the effectiveness of the iodine sign as a predictor of HE and poor functional outcomes.
this study are available from the corresponding author on reasonable request.
Patient Cohort
We prospectively included consecutive SICH patients aged >18 years who were admitted to Beijing Tiantan Hospital between September 2015 and December 2017 in this study. Patients with SICH who underwent noncontrast head CT (NCCT) followed by contrastenhanced dual-energy spectral CTA within 6 hours of symptom onset and follow-up NCCT within 24 hours were eligible for this study ( Figure I in the online-only Data Supplement). Ethics approval was obtained from the local institutional review board, and all patients or their family members provided written informed consent. Patients were excluded from this study if they (1) had secondary ICH, including a vascular malformation, cerebral aneurysm, trauma, brain tumor, hemorrhagic venous infarction, or hemorrhagic transformation of ischemic stroke; (2) had anticoagulant-associated ICH; (3) could not undergo spectral CTA (eg, kidney dysfunction, severe head movement artifact); or (4) did not undergo follow-up CT (3 patients were excluded because of death, 5 patients were excluded because of transfer to another hospital, and 8 patients were excluded for undergoing interventional surgery).
Clinical Data and Outcomes
The patients' demographic data, hypertension assessments, baseline glucose levels, medication use, baseline National Institutes of Health Stroke Scale (NIHSS) scores, and laboratory results were collected by neurologists at the emergency department. The neurological outcomes were determined using a modified Rankin Scale (mRS) at the 1-month follow-up evaluation. We defined a good recovery as 0 to 1 on the mRS, a moderate disability as 2 to 3 on the mRS, and a poor outcome as 4 to 5 on the mRS.
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Imaging Acquisition
All patients underwent CT using a 64-slice Discovery CT750HD scanner (GE Healthcare, Waukesha, WI). First, whole-brain NCCT was performed using the standard single-energy helical mode with 120 kVp, 300 mA, 0.6 s gantry rotation time, and 0.984:1 helical pitch. Then, contrast-enhanced CTA scanning was performed using the dual-energy spectral imaging mode with rapid switching between 80 kVp and 140 kVp. The scanning parameters were as follows: tube current, 375 mA; slice thickness, 5 mm; rotation time, 0.6 s/rotation; collimation thickness, 0.625 mm×64; and scan field-of-view, 25 cm. Both the reconstruction slice thickness and interval were 0.625 mm. The contrast agent Iohexol (300 mgI/mL; Guerbet, France) was used in the spectral CTA scans at a patient weight-dependent dose of 0.7 mL/kg and an injection rate of 6 mL/s. CTA contrast bolus timing was assessed using the SmartPrep (GE Healthcare) semiautomated attenuation-triggered technique. The volumetric CT dose index and dose-length product were recorded after each scan, and the effective radiation dose was 1.86 mSv for 1-time scanning. Finally, follow-up NCCT was performed within 24 hours using the same CT system and parameters as those used for plain CT.
Imaging Analysis
Two radiologists with >5 years of experience who were blinded to the patients' clinical data and outcomes reviewed all plain CT images. They measured hematoma volumes in the initial and follow-up plain CTs at separate sessions; the images were anonymous and randomized to blind the reviewers to the patient identity and the timing of the images (initial or follow-up). The location of the hematoma was evaluated and classified as either lobular or deep, and hematoma volumes were calculated manually by using the ABC/2 formula. The intraventricular hematoma volume was not included in the volume analysis but was recorded based on the modified Graeb score. Absolute ICH growth (follow-up volume-baseline volume) and relative ICH growth ([follow-up volume-baseline volume]/baseline volume) were calculated, and HE was defined as an absolute ICH growth ≥6 mL or a relative growth ≥33%.
Next, a separate team of radiologists, blinded to HE, detected the spot and iodine signs only from the spectral CTA images. Based on the original image of the dual-energy spectral CTA, the spot sign was visualized on spot windows (width, 180; level, 80) according to previously published and validated criteria for single-phase CTA as follows: (1) at least 1 focus (attenuation >120 HU) of any size and morphology within the hematoma, and (2) discontinuity from normal or abnormal vasculature adjacent to the ICH. 16, 17 There was no difference between the single-phase CTA and dual-energy spectral CTA original images. Thus, the delineation of the spot sign was consistent ( Table I in the online-only Data Supplement).
Compared with the spot sign technique, the iodine sign was evaluated using GSI viewer on a standard Advantage Workstation (AW4.6; GE Healthcare) of dual-energy spectral CT. After postprocessing of spectral CTA images, the iodine sign was detected on the iodine-based material decomposition images. We defined a positive iodine sign according to the following criteria: (1) ≥1 enhanced foci within the hematoma of any size and morphology on the iodine-based decomposition image; assessment was made by simple visual inspection and could easily be conducted by nonradiologists. (2) An internal focus IC >7.82 100 µg/mL. The reviewers set a region of interest that covered most of the focus area but did not include the adjacent hematoma. To more accurately measure the focal ICs, the reviewers were allowed to magnify the image (from ×3 to ×5). 
Statistical Analysis
Baseline clinical and radiological characteristic comparisons were conducted between groups of spot sign (+) versus spot sign (−) and iodine sign (+) versus iodine sign (−). Categorical variables were expressed as frequencies (percentages, %), and continuous variables were expressed as the mean±SD or interquartile range according to the normality of the data. Student t test or the Mann-Whitney U test were used to analyze continuous data, and Pearson or Fisher exact tests were used to analyze categorical variables as appropriate. The interobserver reliability was assessed using kappa analysis.
The relationship between HE and both the spot sign and the iodine sign were evaluated by univariate and multivariate logistical regression analyses, odds ratios, and 95% CIs. Adjusted variables in the multivariate logistical model were determined according to a literature review, medical knowledge, and univariate analysis. The predictive abilities of the spot and iodine signs on HE were evaluated using sensitivity, specificity, positive predictive value, and negative predictive value assessments. We also made overall comparisons on different functional outcomes according to the mRS between the iodine sign (+/−) groups using the χ 2 test. All analyses were conducted with SPSS version 19.0 software (IBM, Armonk, NY). Two-tailed P values <0.05 were considered statistically significant.
Results
A total of 91 patients who were consecutively subjected to spectral CTA were included in our study. The mean age of the participants was 53.82±12.83 years; 64 patients (70.3%) were men, and 27 patients (29.7%) were women. Sex was imbalanced between the 2 groups. The median NIHSS score at admission was 9.0 (range, 5.0-13.0) points. There were no significant differences in the distributions of age, sex, past medical history, glucose levels, blood pressure, location of hematoma, and laboratory results between the spot sign-positive and spot sign-negative groups. Patients with a positive spot sign had a higher onset NIHSS score (11. A positive spot sign was detected in 38.5% (35/91) of the subjects, and a positive iodine sign was detected in 57.1% (52/91) of the patients. Except for 4 patients, all subjects with a positive spot sign also had a positive iodine sign. The interobserver agreements for the detection of spot and iodine signs were 0.89 and 0.93, respectively.
Significant hematoma growth was present in 48.5% (47/91) of patients with SICH. All of the patients with a positive iodine sign and a positive spot sign had significantly increased hematoma volumes according to the follow-up NCCT performed within 24 hours (P<0.001). However, patients with a negative spot sign had larger increases in their hematoma volume than patients with a negative iodine sign (111.3±38.8% versus 100.6±33.9%; Figure 2 ). Of the entire group, poor outcomes (mRS, 4-5) occurred in 37.4% (34/91) of the patients.
Relationship Between HE and Predictive Performances of the Spot and Iodine Signs
Univariate and multivariate logistical regression analyses were performed to assess the relationships between various clinical and radiological parameters and HE (Table 2) . Univariate analysis showed an odds ratio value of 13.77 (4.56-41.56; P<0.001) for the spot sign, whereas the odds ratio value for the iodine sign was 41.81 (11.87-147.31; P<0.001). According to a literature review and univariate analysis, the baseline hematoma volume, age, NIHSS score at admission, activated partial thromboplastin time, and glucose level were utilized as adjusted variables in the multivariate logistical model. Multivariate analysis showed that both the GSI iodine sign and the CTA spot sign were associated with HE, with odds ratio values of 53.67 (11.88-242.42; P<0.001) and 12.09 (3.87-37.77; P<0.001), respectively. The adjusted factors showed no significant associations with HE (P>0.05).
The predictive performance of the iodine sign showed that it maintained a higher sensitivity (91.5% versus 61.8%), negative predictive value (89.7% versus 69.9%) and accuracy (85.7% versus 75.8%) for detecting HE than the spot sign (Table 3) . To compare the predictive performance between the spot sign and iodine sign directly, the receiver operating characteristic curve has been performed ( Figure III in the onlineonly Data Supplement). The baseline hematoma volume and NIHSS have been adjusted in this curve. The area under the curves of the spot sign and the iodine sign is 0.83 (0.74-0.91) and 0.89 (0.82-0.96), respectively. The P value is 0.23. There was no statistically significant between the spot sign and iodine sign in the predictive performance of HE.
Iodine Sign and Clinical Outcomes
We also analyzed the relationships between clinical outcomes and the spot and iodine signs using the mRS score at discharge (Figure 3 ). The frequencies of poor outcomes (severely disabled and vegetative state) were significantly higher in patients with a positive iodine sign than in patients with a negative iodine sign (61.5% versus 5.1%; χ 2 =29.969; P<0.001). There were no significant differences in outcomes based on the spot sign (48.6% versus 30.4%; χ 2 =3.02; P=0.081). In the poor outcome group, a positive iodine sign was present in 32 (94.1%) patients, and a positive spot sign was present in 17 (50%) patients. We also compared the predictive Figure 1 . Diagnostic criteria for the iodine sign in patients with spontaneous intracerebral hemorrhage. Based on iodine decomposition image of spectral computed tomography angiography (CTA), ≥1 visible enhanced foci discontinuity from adjacent vasculature within the hematoma was selected first. Then a region of interest (ROI) was set on the foci for the leakage of the contrast medium into the hematoma. The iodine concentration (IC) in the ROI was determined, and IC >7.82 100 µg/mL was considered as a positive iodine sign.
performances of poor outcomes between the iodine signpositive and spot sign-positive groups ( Table 3 ). The positive iodine sign showed a higher sensitivity (61.5% versus 48.6%), specificity (94.9% versus 69.6%), positive predictive value (94.1% versus 50%), and accuracy (75.8% versus 61.5%) for predicting poor outcomes than the spot sign. In the other clinical group, the difference in the proportion of patients was not significant (P>0.05).
Discussion
Hematomas progressively enlarge because of vessel damage at either the original source or at the adjacent microvessel. [18] [19] [20] When the vessel is damaged, the contrast leaks out, but the hematoma density may cover the early contrast extravasation. The GSI technique uses a single-source dual-energy scanner with a rapid kVp switching system, 21 which can effectively separate iodine, calcium, and other materials, such as Relationship between the change in volume relative to baseline (radio) and both predictive signs (iodine sign and spot sign). The hematoma volume change during the 24-hour period after admission in the imaging study for the iodine sign (left) and the spot sign (right).
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blood. [21] [22] [23] [24] On iodine-based images, the hematoma density was suppressed to visualize the early iodine contrast extravasation. In our previous study, 25 we found that the IC in the spot sign (>7.82 100 µg/mL) was associated with HE. Thus, we defined a positive iodine sign as having an IC >7.82 (100 µg/mL) inside the focus based on the iodine map, which reflected the early iodine contrast extravasation.
In our study, the overall spot sign prevalence rate was ≈38.5%, which was within the range of previously reported rates (18% to 72%). 16, 26 Visualization of contrast extravasation within a hematoma, or the spot sign, has been previously characterized and identified as an independent predictor of early HE. 17 However, prior studies have demonstrated that the sensitivity of the spot sign for predicting HE ranges from 26.2% to 73%, and the accuracy ranges from 43% to 81%, 27 which suggests that the predictive performance of the spot sign lacks accuracy. Furthermore, a prospective multicenter study showed that 22% of spot sign-negative patients underwent HE, 28 with high false-negative rates, likely underestimating the true number of patients with contrast extravasation. In addition, we also found hematoma growth in the spot signnegative group (Figure 1) , suggesting that the extravasated contrast gradually accumulated before the spot sign could be detected. Early contrast extravasation (iodine sign) may accurately reflect the ongoing bleeding in the hematoma.
The iodine sign, detected by dual-energy imaging with Gemstone spectral CT, maintained a higher accuracy (85.7% versus 75.8%) for predicting HE than the CTA spot sign. The spot sign is visualized as ongoing bleeding inside the hematoma. 18 However, the early ongoing bleeds could not be visualized by hematoma density interference, which could explain why hematomas grew in the spot sign-negative group. GSI generates monochromatic images using energy levels of 40 kVp to 140 kVp. 22 Each energy level has a unique CT attenuation value that transforms the relative CT value into an absolute CT value, 29 which allowed us to capture the early foci of blood extravasation suppressing the hematoma density. No previous methods 15, [30] [31] [32] could detect early contrast extravasation, and the details of these methods were not provided. But we also found that the predictive performance of HE was no statistically significant between spot sign and iodine sign. This may be because of the small sample and need to be clarified in clinical practice. Therefore, our definition of the iodine sign as ≥1 enhanced foci within the hematoma with IC >7.82 100 µg/ mL based on dual-energy spectral CT may be a reliable and useful imaging marker for predicting HE and showed a minor improved detection rate than that of the spot sign.
Our findings suggest that the iodine sign identifies early ongoing contrast extravasation with IC >7.82 100 µg/mL and is a predictor of hematoma growth in patients with SICH. Previous studies have suggested that HE may be secondary to mechanical shearing of small penetrating arteries and neighboring vessels. 33 From a physiological point of view, early and ongoing contrast extravasation in the hematoma may reflect a rupture of the adjacent microvessels. As the hematoma is formed and serum is sequestered outside the hematoma, the bleed was found to become hyper-intense on CT scan, 34 and the damage to the microvessels became invisible because of hematoma density interference. The presence of the iodine sign in a GSI that suppressed hematoma density may suggest the presence of ruptured microvessels. This may explain the predictive value of the GSI iodine sign in SICH patients.
Recently, a modified spot sign 9, 19, 35 visualized with delayed-phase CT (2-5 minutes after single-phase CTA) was reported to improve the accuracy of detecting HE. Both the sensitivity and specificity of the modified spot sign were improved with the evaluation of delayed-phase CT. However, compared with delayed-phase CT, GSI has several advantages: (1) it captures early extravasation foci, (2) it requires less time (2 versus 5 minutes), and (3) it utilizes a lower radiation dosage. Our study indicates that the iodine sign detected by GSI is clearly defined, has high accuracy, has a convenient scanning time, and requires a low radiation dose, making it a useful predictor of hematoma growth.
Our study does have some limitations. First, it was a prospective study with a relatively small sample size conducted at a single center. The IC of the iodine sign, including the measurement method and contrast dose, was based on GSI in our center, and our findings thus require external validation with a larger cohort in future studies. Moreover, we must note that the predictive value of the iodine sign does not reflect the performance of the spot sign on single-phase CTA, as iodine sign observations were based on dual-energy imaging (iodine-based images). Second, the patients who died within 24 hours were excluded from our study because follow-up CT could not be performed. This may have led to underestimations of the spot sign-and iodine sign-positive predictive values for poor outcomes. Also, there were several dissimilarities between the 2 groups, such as baseline hematoma volume and NIHSS. Although we included those variables in multivariate logistic analysis and found no significant associations with HE (P>0.05), these factors may be clinically relevant and require further external validation.
Conclusions
In conclusion, with an improved detection rate on GSI, the iodine sign may represent a sensitive and accurate predictor of HE and poor outcomes. GSI is an advanced, highly accurate method, that requires a short wait time and utilizes low radiation dosages. We expect this method to be useful for predicting HE in ICH patients. The relatively high frequency of the iodine sign may also limit its clinical utility, but it may be useful in future trials of hemostatic therapy. 
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